2020.Apr.11
The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by Ministry of Food and Drug Safety of South Korea to proceed Phase III human clinical study
Date of occurrence of the event: Apr 10, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: No applicable Cause of occurrence: The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by Ministry of Food and Drug Safety of South Korea to […]
This article is password protected.
To view the content, please enter your password in the field below